LONDON Jan 24 GlaxoSmithKline said on
Friday European regulators had given the green light to its
once-weekly diabetes drug albiglutide, which it is marketing as
Albiglutide belongs to the same class of injectable GLP-1
drugs as Victoza, from Novo Nordisk, and Byetta and
Bydureon, from Bristol-Myers Squibb and AstraZeneca
A positive recommendation for a drug by the European
Medicines Agency is generally followed by a marketing
authorisation by the European Commission. GSK said a final
decision was anticipated later this quarter.
Last year regulators in the United States pushed back an
approval decision on the drug until April 15.